Phase 1 Kidney Cancer Trial, Recruiting (NCT06966024)

Phase 1 Kidney Cancer Trial, Recruiting NCT06966024 Sponsor: Deciphera Pharmaceuticals, LLC Condition: Kidney Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06966024 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Kidney Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with advanced or metastatic kidney cancer (renal cell carcinoma), bladder/urinary tract cancer (urothelial cancer), or prostate cancer that no longer responds to hormone-reducing treatment (castration-resistant prostate cancer)
You are able to swallow and digest tablets or capsules by mouth
If you are a woman who could become pregnant, you must have a negative pregnancy test before joining, and all participants must agree to use contraception as required by the trial
Your organs (such as kidneys, liver, and heart) and body chemical levels (electrolytes) are working well enough to meet the trial's standards (confirm with trial site)

Who may not be able to join:

You have received certain cancer treatments or experimental therapies within a specific period of time before starting this trial's study drug (confirm with trial site for exact timeframes)
You have a heart condition that affects how well your heart functions
You have had a major surgical procedure within 28 days before you would start taking the study drug

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Team, Deciphera Pharmaceuticals, LLC

Phone: 888-724-3274

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06966024

Sponsor: Deciphera Pharmaceuticals, LLC

Phase: Phase 1

Status: Recruiting

Condition: Kidney Cancer

Trial contact: 888-724-3274

More information: https://clinicaltrials.gov/study/NCT06966024

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with advanced or metastatic kidney cancer (renal cell carcinoma), bladder/urinary tract cancer (urothelial cancer), or prostate cancer that no longer responds to hormone-reducing treatment (castration-resistant prostate cancer)
You are able to swallow and digest tablets or capsules by mouth
If you are a woman who could become pregnant, you must have a negative pregnancy test before joining, and all participants must agree to use contraception as required by the trial
Your organs (such as kidneys, liver, and heart) and body chemical levels (electrolytes) are working well enough to meet the trial's standards (confirm with trial site)

Who may not be able to join:

You have received certain cancer treatments or experimental therapies within a specific period of time before starting this trial's study drug (confirm with trial site for exact timeframes)
You have a heart condition that affects how well your heart functions
You have had a major surgical procedure within 28 days before you would start taking the study drug

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Deciphera Pharmaceuticals, LLC

Registry

ClinicalTrials.gov

Start date

27 August 2025

Est. completion

1 February 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants with Dose-limiting Toxicities (DLTs); Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs); Number of Participants With Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov